What it is
Dihexa is an experimental compound based on angiotensin IV, a fragment of a blood pressure hormone. It was developed at Washington State University.
In lab studies it appears to boost the HGF/c-Met pathway, which helps brain cells form new connections. It is promoted online as a memory enhancer.
US regulatory status
Not FDA-approved. The FDA removed it from its Category 2 compounding list in April 2026, with an advisory committee review planned by early 2027; it is not currently an accepted bulk substance for compounding.
What the research shows
Evidence is limited to cell and animal studies, such as improved learning in rats with memory problems. There are no published human clinical trials. The HGF/c-Met pathway is also involved in some cancers, which is a theoretical safety concern.
How it is given
Oral, topical or injection (unapproved)
Commonly reported side effects
- No reliable human data on side effects
- Theoretical concern about cancer-related growth pathways
- Risk of contaminated or mislabeled products
Questions to ask your provider
- What does the research really show about dihexa in humans?
- Are there FDA-approved treatments for my goal that have stronger evidence?
- What are the risks of products labeled "research use only," and how would I know what is really in them?